Silencing Myostatin Using Cholesterol-conjugated siRNAs Induces Muscle Growth

Molecular Therapy Nucleic Acids

Volumn 5, Issue 8, 2016, Pages e342-

  Khan, Tayeba ^a   Weber, Hans ^a   Dimuzio, Jillian ^a   Matter, Andrea ^a   Dogdas, Belma ^a   Shah, Tosha ^a   Thankappan, Anil ^a   Disa, Jyoti ^a   Jadhav, Vasant ^a   Lubbers, Laura ^a   Sepp Lorenzino, Laura ^a   Strapps, Walter R ^a   Tadin Strapps, Marija ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

cholesterol conjugate; muscle; myostatin; siRNA; systemic delivery

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATINE KINASE; MYOSTATIN; SMALL INTERFERING RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; FEMALE; GASTROCNEMIUS MUSCLE; GENE SILENCING; LUCIFERASE ASSAY; MOUSE; MUSCLE FATIGUE; MUSCLE GROWTH; MUSCLE LEVEL; MUSCLE MASS; MUSCLE SIZE; MUSCLE STRENGTH; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SKELETAL MUSCLE; SOLEUS MUSCLE; TRICEPS BRACHII MUSCLE;

EID: 84982735874     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2016.55     Document Type: Article

References (52)

1. Bakhtiyari, S, Haghani, K, Basati, G and Karimfar, MH (2013). siRNA therapeutics in the treatment of diseases. Ther Deliv 4: 45-57.
2. Burnett, JC and Rossi, JJ (2012). RNA-based therapeutics: current progress and future prospects. Chem Biol 19: 60-71.
3. Lares, MR, Rossi, JJ and Ouellet, DL (2010). RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol 28: 570-579.
4. Frank-Kamenetsky, M, Grefhorst, A, Anderson, NN, Racie, TS, Bramlage, B, Akinc, A et al. (2008). Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 105: 11915-11920.
5. Khoury, M, Louis-Plence, P, Escriou, V, Noel, D, Largeau, C, Cantos, C et al. (2006). Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum 54: 1867-1877.
6. Wolfrum, C, Shi, S, Jayaprakash, KN, Jayaraman, M, Wang, G, Pandey, RK et al. (2007). Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25: 1149-1157.
7. Schiffelers, RM, Ansari, A, Xu, J, Zhou, Q, Tang, Q, Storm, G et al. (2004). Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32: e149.
8. Reich, SJ, Fosnot, J, Kuroki, A, Tang, W, Yang, X, Maguire, AM et al. (2003). Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 9: 210-216.
9. Zhang, X, Shan, P, Jiang, D, Noble, PW, Abraham, NG, Kappas, A et al. (2004). Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J Biol Chem 279: 10677-10684.
10. Tan, PH, Yang, LC, Shih, HC, Lan, KC and Cheng, JT (2005). Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther 12: 59-66.
11. Liang, Y, Gao, H, Lin, SY, Goss, JA, Brunicardi, FC and Li, K (2010). siRNA-based targeting of cyclin E overexpression inhibits breast cancer cell growth and suppresses tumor development in breast cancer mouse model. PLoS One 5: e12860.
12. Golzio, M, Mazzolini, L, Moller, P, Rols, MP and Teissié, J (2005). Inhibition of gene expression in mice muscle by in vivo electrically mediated siRNA delivery. Gene Ther 12: 246-251.
13. Watts, LM, Manchem, VP, Leedom, TA, Rivard, AL, McKay, RA, Bao, D et al. (2005). Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. Diabetes 54: 1846-1853.
14. Zanardi, TA, Han, SC, Jeong, EJ, Rime, S, Yu, RZ, Chakravarty, K et al. (2012). Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2. J Pharmacol Exp Ther 343: 489-496.
15. Trembley, JH, Unger, GM, Tobolt, DK, Korman, VL, Wang, G, Ahmad, KA et al. (2011). Systemic administration of antisense oligonucleotides simultaneously targeting CK2 and ?' subunits reduces orthotopic xenograft prostate tumors in mice. Mol Cell Biochem 356: 21-35.
16. Karras, JG, McGraw, K, McKay, RA, Cooper, SR, Lerner, D, Lu, T et al. (2000). Inhibition of antigen-induced eosinophilia and late phase airway hyperresponsiveness by an IL-5 antisense oligonucleotide in mouse models of asthma. J Immunol 164: 5409-5415.
17. Laws, N, Cornford-Nairn, RA, Irwin, N, Johnsen, R, Fletcher, S, Wilton, SD et al. (2008). Long-term administration of antisense oligonucleotides into the paraspinal muscles of mdx mice reduces kyphosis. J Appl Physiol (1985) 105: 662-668.
18. Gebski, BL, Mann, CJ, Fletcher, S and Wilton, SD (2003). Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum Mol Genet 12: 1801-1811.
19. Hagstrom, JE, Hegge, J, Zhang, G, Noble, M, Budker, V, Lewis, DL et al. (2004). A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs. Mol Ther 10: 386-398.
20. Kawakami, E, Kawai, N, Kinouchi, N, Mori, H, Ohsawa, Y, Ishimaru, N et al. (2013). Local applications of myostatin-siRNA with atelocollagen increase skeletal muscle mass and recovery of muscle function. PLoS One 8: e64719.
21. Kawakami, E, Kinouchi, N, Adachi, T, Ohsawa, Y, Ishimaru, N, Ohuchi, H et al. (2011). Atelocollagen-mediated systemic administration of myostatin-targeting siRNA improves muscular atrophy in caveolin-3-deficient mice. Dev Growth Differ 53: 48-54.
22. Sartori, R, Milan, G, Patron, M, Mammucari, C, Blaauw, B, Abraham, R et al. (2009). Smad2 and 3 transcription factors control muscle mass in adulthood. Am J Physiol Cell Physiol 296: C1248-C1257.
23. Stitt, TN, Drujan, D, Clarke, BA, Panaro, F, Timofeyva, Y, Kline, WO et al. (2004). The IGF-1/ PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 14: 395-403.
24. Lin, J, Arnold, HB, Della-Fera, MA, Azain, MJ, Hartzell, DL and Baile, CA (2002). Myostatin knockout in mice increases myogenesis and decreases adipogenesis. Biochem Biophys Res Commun 291: 701-706.
25. Schuelke, M, Wagner, KR, Stolz, LE, Hübner, C, Riebel, T, Kömen, W et al. (2004). Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 350: 2682-2688.
26. McPherron, AC and Lee, SJ (1997). Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 94: 12457-12461.
27. Zhou, X, Wang, JL, Lu, J, Song, Y, Kwak, KS, Jiao, Q et al. (2010). Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142: 531-543.
28. Chiu, CS, Peekhaus, N, Weber, H, Adamski, S, Murray, EM, Zhang, HZ et al. (2013). Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents. J Gerontol A Biol Sci Med Sci 68: 1181-1192.
29. Heineke, J, Auger-Messier, M, Xu, J, Sargent, M, York, A, Welle, S et al. (2010). Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation 121: 419-425.
30. Zhang, L, Rajan, V, Lin, E, Hu, Z, Han, HQ, Zhou, X et al. (2011). Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J 25: 1653-1663.
31. Rüegg, MA and Glass, DJ (2011). Molecular mechanisms and treatment options for muscle wasting diseases. Annu Rev Pharmacol Toxicol 51: 373-395.
32. Engelen, MP, Schols, AM, Baken, WC, Wesseling, GJ and Wouters, EF (1994). Nutritional depletion in relation to respiratory and peripheral skeletal muscle function in out-patients with COPD. Eur Respir J 7: 1793-1797.
33. Bailey, JL, Zheng, B, Hu, Z, Price, SR and Mitch, WE (2006). Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J Am Soc Nephrol 17: 1388-1394.
34. Asp, ML, Tian, M, Wendel, AA and Belury, MA (2010). Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice. Int J Cancer 126: 756-763.
35. Sharma, M, Kambadur, R, Matthews, KG, Somers, WG, Devlin, GP, Conaglen, JV et al. (1999). Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. J Cell Physiol 180: 1-9.
36. Rodgers, BD, Interlichia, JP, Garikipati, DK, Mamidi, R, Chandra, M, Nelson, OL et al. (2009). Myostatin represses physiological hypertrophy of the heart and excitationcontraction coupling. J Physiol 587(Pt 20): 4873-4886.
37. Artaza, JN, Reisz-Porszasz, S, Dow, JS, Kloner, RA, Tsao, J, Bhasin, S et al. (2007). Alterations in myostatin expression are associated with changes in cardiac left ventricular mass but not ejection fraction in the mouse. J Endocrinol 194: 63-76.
38. Morissette, MR, Cook, SA, Foo, S, McKoy, G, Ashida, N, Novikov, M et al. (2006). Myostatin regulates cardiomyocyte growth through modulation of Akt signaling. Circ Res 99: 15-24.
39. Whittemore, LA, Song, K, Li, X, Aghajanian, J, Davies, M, Girgenrath, S et al. (2003). Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 300: 965-971.
40. Weber, H, Rauch, A, Adamski, S, Chakravarthy, K, Kulkarni, A, Dogdas, B et al. (2012). Automated rodent in situ muscle contraction assay and myofiber organization analysis in sarcopenia animal models. J Appl Physiol (1985) 112: 2087-2098.
41. Tang, Y, Hamed, HA, Poklepovic, A, Dai, Y, Grant, S and Dent, P (2012). Poly(ADPribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors. Mol Pharmacol 82: 322-332.
42. Honma, K, Iwao-Koizumi, K, Takeshita, F, Yamamoto, Y, Yoshida, T, Nishio, K et al. (2008). RPN2 gene confers docetaxel resistance in breast cancer. Nat Med 14: 939-948.
43. Nakazawa, K, Nemoto, T, Hata, T, Seyama, Y, Nagahara, S, Sano, A et al. (2007). Single-injection ornithine decarboxylase-directed antisense therapy using atelocollagen to suppress human cancer growth. Cancer 109: 993-1002.
44. Hanai, K, Kurokawa, T, Minakuchi, Y, Maeda, M, Nagahara, S, Miyata, T et al. (2004). Potential of atelocollagen-mediated systemic antisense therapeutics for inflammatory disease. Hum Gene Ther 15: 263-272.
45. Kawata, E, Ashihara, E, Kimura, S, Takenaka, K, Sato, K, Tanaka, R et al. (2008). Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer. Mol Cancer Ther 7: 2904-2912.
46. Kinouchi, N, Ohsawa, Y, Ishimaru, N, Ohuchi, H, Sunada, Y, Hayashi, Y et al. (2008). Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass. Gene Ther 15: 1126-1130.
47. Lee, SJ and McPherron, AC (2001). Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 98: 9306-9311.
48. Mendias, CL, Marcin, JE, Calerdon, DR and Faulkner, JA (2006). Contractile properties of EDL and soleus muscles of myostatin-deficient mice. J Appl Physiol (1985) 101: 898-905.
49. Soutschek, J, Akinc, A, Bramlage, B, Charisse, K, Constien, R, Donoghue, M et al. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178.
50. Lorenz, C, Hadwiger, P, John, M, Vornlocher, HP and Unverzagt, C (2004). Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 14: 4975-4977.
51. Krützfeldt, J, Rajewsky, N, Braich, R, Rajeev, KG, Tuschl, T, Manoharan, M et al. (2005). Silencing of microRNAs in vivo with 'antagomirs'. Nature 438: 685-689.
52. Tadin-Strapps, M, Peterson, LB, Cumiskey, AM, Rosa, RL, Mendoza, VH, Castro-Perez, J et al. (2011). siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids. J Lipid Res 52: 1084-1097.